Heart Failure

Sotagliflozin (Inpefa) is an orally administered dual SGLT1/2 inhibitor that reduces the risk of death due to heart failure.

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

This marks the first time that experts have defined cardiovascular-kidney-metabolic syndrome, including the overlap of cardiovascular disease with kidney disease, type 2 diabetes, and obesity.

Patients under the care of psychiatric facilities, particularly those taking antipsychotic and antidepressant medications, face the risk of prolonged QTc intervals.

Study findings indicated that many health care facilities are recovering from the COVID-19 pandemic and shortage of staff, which has caused door-to-balloon times to lag.

Routine yoga therapy has shown endurance, strength, balance, symptom stability and quality of life improvements in individuals with heart failure.

An average patient with heart failure can take up to 6 medications for guideline-directed medical therapy; however, they may have other comorbidities that require pharmacologic management.

Heart disease prevention efforts should acknowledge non-biological factors that can cause issues within cardiovascular health rather than relying on decreasing socioeconomic disparities.

The Phase 2 KARDIA-1 Study met its primary endpoint of lower systolic blood pressure with the use of zilebesiran.

Black women had the highest rates of obesity-related cardiovascular disease deaths whereas other racial groups had more men experiencing obesity-related CVD deaths than women.

Results from the VALOR-HCM LTE trial at 56 weeks demonstrated that with longer follow-up, mavacamten continued to reduce patient eligibility for invasive septal reduction therapy.

After 1 year of treatment, semaglutide significantly improved physical function, which can improve quality of life outcomes and risk of death.

Ferric carboxymaltose was not found to have a significant impact on 6-minute walk distance, which is part of the primary outcome’s hierarchical composite of death and hospitalizations from heart failure.

Stressful life events and poor sleeping patterns are linked to the development of atrial fibrillation in older women.

Pharmacists can actively engage in the implementation of the Comprehensive Diagnostics and Examinations in Acute Coronary Syndromes pathway within the hospital or health care system.

Notably, 65% of the participants experiencing pain at the 2-month follow up were also experiencing pain at their 12-month follow up, suggesting persistent and long-term pain.

Session at NACDS Total Store Expo discusses how pharmacies can leverage their accessibility to decrease diet-related diseases through health and wellness.

Research shows a substantial difference between overall deaths of men and women at 43% and 28.2%, respectively, from cardiovascular disease associated with particulate matter.

Study shows that as patients with type 2 diabetes lost more teeth, their risk of heart failure grew.

Updated guidelines, comprehensive review, and an investment of resources into pediatric preventive cardiology programs could help provide successful care.

Notably, patients with transthyretin cardiac amyloidosis had higher rates of heart failure hospitalizations, including patients treated with tafamidis.

Guidelines provide clear recommendation that oral transitional therapy is at least as effective as intravenous-only therapy for the treatment of infective endocarditis.

The lowering melatonin levels in patients with heart disease is one example of how heart conditions can influence systems throughout the body.

The risk of death from both overall and cardiovascular causes was also reduced in patients who underwent complete revascularization.

The risk could double if the conditions are met, with deaths more common in women and those aged 80 and older.

Pharmacists should provide guidance on issues such as proper drug disposal and potential drug interactions.

Quitting treatment may significantly improve severe hypertension in patients with hepatocellular carcinoma.

The risk of heart failure was higher in low- and middle-income countries when compared to high-income countries.

Population well-being was associated with cardiovascular disease morality and rates of conditions such as hypertension, diabetes, and obesity.

The novel treatment may be able to generate new cardiac tissue to create a functional human heart muscle.